Tocolytic therapy refers to the use of medications that suppress uterine contractions during preterm labor, and its primary goal is surprisingly modest: not to prevent preterm birth altogether, but to delay delivery long enough to give corticosteroids time to mature the fetal lungs and, when necessary, to transfer the mother to a hospital with a neonatal intensive care unit. That 48-hour window is the core objective, and while multiple drug classes can achieve it, none has been shown to definitively improve long-term outcomes on its own. The story of tocolysis is really the story of buying time and what clinicians do with it.
Why 48 Hours Matters More Than Weeks
The modest ambition of tocolytic therapy often confuses people who assume the point is to keep the baby in the womb until full term. In practice, clinicians prescribe tocolytics to suppress contractions for a short window, typically 48 hours, so that a full course of antenatal corticosteroids can be administered. Those steroids accelerate fetal lung development and reduce the risk of respiratory distress syndrome, which is one of the leading causes of illness and death in very premature infants. The 48-hour delay also creates a window for magnesium sulfate to be given for fetal neuroprotection and for arranging an in-utero transfer to a facility with specialized neonatal care.1PubMed Central. Tocolytics for delaying preterm birth: a network meta-analysis
There is ample evidence that tocolytic drugs can delay delivery for at least this long, even though definitive proof that tocolysis alone improves final outcomes is lacking.2PubMed. Use of tocolytics: what is the benefit of gaining 48 hours for the fetus? The benefit comes from what those 48 hours enable. Cost-effectiveness analyses have found that giving both corticosteroids and tocolytics together results in lower costs and better outcomes compared with treating neither, and even compared with giving corticosteroids without tocolysis.3PubMed Central. Cost-effectiveness of antenatal corticosteroids and tocolytic agents in the management of preterm birth: A systematic review The WHO guideline panel has echoed this reasoning, noting that although no single tocolytic class appears to reduce perinatal death on its own, the indirect benefit of extending the interval between corticosteroid administration and birth is associated with lower neonatal mortality.4The Lancet. Updated WHO recommendations on antenatal corticosteroids and tocolytic therapy for improving preterm birth outcomes
The Drug Classes and How They Compare
Several classes of medication are used as tocolytics, and choosing among them involves balancing effectiveness, side-effect profiles, availability, and cost. No single agent has emerged as a clear overall winner, which is part of why practice varies so much around the world.
Calcium Channel Blockers
Nifedipine, a calcium channel blocker originally developed for high blood pressure, has become one of the most widely used tocolytics globally. It works by blocking the calcium flow that myometrial smooth muscle cells need in order to contract. A systematic review and meta-analysis found that nifedipine reduced the risk of delivery within seven days and before 34 weeks compared with older beta-agonist drugs, and was also linked to lower rates of respiratory distress syndrome, necrotizing enterocolitis, and neonatal intensive care admissions.5American Journal of Obstetrics and Gynecology. Nifedipine in the management of preterm labor: a systematic review and metaanalysis That same review found no difference in tocolytic effectiveness between nifedipine and magnesium sulfate, but nifedipine caused fewer maternal side effects than both magnesium sulfate and beta-agonists.
However, the picture is not entirely straightforward. A placebo-controlled randomized trial found no significant difference between nifedipine and placebo in preventing delivery before 37 weeks or in delivering at least 48 hours after treatment began.6Obstetrics & Gynecology. Nifedipine for Acute Tocolysis of Preterm Labor: A Placebo-Controlled Randomized Trial This is a genuinely surprising finding and highlights a recurring problem in tocolysis research: many early trials compared drugs head-to-head without a placebo arm, making it hard to know how much of the observed effect was the drug versus how much was the natural course of preterm labor, which often resolves on its own. When the common side effects of nifedipine are considered, including tachycardia, low blood pressure, and headache, the cost-benefit calculation is worth thinking about carefully.7PubMed Central. Efficacy and Safety of Nifedipine as a Tocolytic Agent in Preterm Labor
Oxytocin Receptor Antagonists
Atosiban is the main drug in this class. It blocks the oxytocin receptor on uterine muscle cells, directly suppressing the contraction signal. A randomized, double-blind, placebo-controlled trial found that significantly more women treated with atosiban remained undelivered and did not need rescue tocolysis at 24 hours, 48 hours, and seven days compared with placebo, with the benefit most consistent at gestational ages of 28 weeks and beyond.8PubMed. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue Atosiban’s appeal lies in its relatively clean side-effect profile compared with beta-agonists. It is widely used in Europe but has not been approved in the United States. Even atosiban, however, is not without risk. Rare cases of non-cardiogenic pulmonary edema have been reported in women receiving the drug.9PubMed Central. Non-Cardiogenic Pulmonary Edema Due to Administration of Atosiban
Beta-Adrenergic Agonists
Terbutaline and ritodrine belong to this class, which was among the first to be used for tocolysis. These drugs relax the uterus by stimulating beta-2 receptors on smooth muscle cells, but the same receptors exist throughout the body, which is why side effects are common. A meta-analysis comparing nifedipine to terbutaline found nifedipine more effective at delaying delivery by at least 48 hours, and maternal heart rate increased far less with nifedipine than with terbutaline.10Journal of the Medical Association of Thailand. Safety and efficacy of oral nifedipine versus terbutaline injection in preterm labor Other comparisons have shown similar effectiveness between the two drugs but consistently more side effects from terbutaline, except for low blood pressure, which was more common with nifedipine.11PubMed. Terbutaline versus nifedipine for prolongation of pregnancy in patients with preterm labor
Pulmonary edema is the most feared complication of beta-agonist tocolysis. With ritodrine, reported rates range widely depending on the study and duration of therapy, and risk increases with tocolysis lasting longer than 24 hours, concurrent corticosteroid use, large volumes of intravenous fluid, and multiple pregnancies.12Case Reports in Women’s Health. Maternal pulmonary edema after 46 h of ritodrine hydrochloride administration: A case report These concerns have pushed many clinicians toward nifedipine or atosiban as first-line agents.
Prostaglandin Synthesis Inhibitors
Indomethacin, a nonsteroidal anti-inflammatory drug, is an effective tocolytic but carries specific fetal risks that limit its use to early gestational ages, generally before 32 weeks. The drug inhibits prostaglandin production, which is involved in triggering contractions. However, prostaglandins also play a crucial role in keeping the fetal ductus arteriosus open, a blood vessel that allows blood to bypass the lungs before birth. A study of preterm infants exposed to indomethacin found significantly higher rates of necrotizing enterocolitis, intracranial hemorrhage, and patent ductus arteriosus requiring surgical repair compared with unexposed infants.13PubMed. Neonatal complications after the administration of indomethacin for preterm labor In extreme cases, prolonged indomethacin use has been associated with complete closure of the fetal ductus arteriosus even after the drug is stopped.14PubMed. Indomethacin and fetal ductus arteriosus: complete closure after cessation of prolonged therapeutic course Because of these risks, indomethacin tends to be reserved for short courses at earlier gestational ages where its potent tocolytic effect is most needed and fetal ductal sensitivity is lower.
When Tocolysis Should Not Be Used
Tocolytics are not appropriate for every case of preterm contractions. Common maternal contraindications include preeclampsia or gestational hypertension with severe features, active hemorrhage, and significant heart disease. On the fetal side, tocolysis is contraindicated when gestational age is past 37 weeks, when the fetus has died or has a lethal anomaly, when there is clinical evidence of chorioamnionitis (infection of the membranes), and when there are signs of acute or chronic fetal compromise.15Obstetrics: Normal and Problem Pregnancies. Preterm Labor and Birth In these situations, the risks of delaying delivery outweigh any benefit from buying time.
The presence of infection is particularly important. A retrospective study found that inflammatory and infectious markers, including elevated C-reactive protein, bacterial vaginosis, and chorioamnionitis on placental examination, were all significantly more common in women who failed to respond to tocolysis. When these risk factors were absent, long-term tocolysis was able to prolong gestation beyond seven days, but when infection was driving the preterm labor, the drugs were far less effective.16PubMed. Inflammatory and infectious risk factors are associated with the response to tocolysis in patients with preterm labor This makes biological sense: if the body is trying to expel the pregnancy because of an infection, suppressing contractions pharmacologically fights the body’s protective mechanism without addressing the underlying threat.
Why Maintenance Tocolysis Does Not Work
A logical question after the initial 48-hour course is whether continuing tocolytics for days or weeks might keep the pregnancy going even longer. The answer, based on the available evidence, is no. An individual participant data meta-analysis of six randomized controlled trials involving nearly 800 women found that maintenance tocolysis with nifedipine, compared with placebo or no treatment, made no difference in perinatal death, serious neonatal complications, or the duration of pregnancy prolongation.17PubMed. Nifedipine maintenance tocolysis and perinatal outcome: an individual participant data meta-analysis Based on these results, maintenance tocolysis is not recommended for routine use. Despite this, surveys of clinical practice show that the majority of obstetric units still do it, at least in certain situations. An Austria-wide survey found that over 90% of obstetric units reported performing maintenance tocolysis, although most said they reserved it for specific indications rather than using it routinely.18PubMed Central. Differences between Current Clinical Practice and Evidence-Based Guideline Recommendations Regarding Tocolysis – an Austria-wide Survey The gap between evidence and practice in this area is wide and persistent.
Combining Two Tocolytics at Once
If one tocolytic is good, would two be better? The evidence here is essentially a blank page. A Cochrane review found that it is unclear whether combining tocolytic drugs offers any advantage to the mother or newborn, largely because no large, well-designed trials have addressed the question. Critically, there are no trials of combination regimens using the most commonly used agents, nifedipine and atosiban, together.19PubMed Central. Combination of tocolytic agents for inhibiting preterm labour In the absence of evidence, combining tocolytics also carries the risk of stacking side effects. The risk of pulmonary edema with beta-agonists, for instance, increases when other tocolytics or corticosteroids are given concurrently. Until solid trial data emerge, combining tocolytics remains off-evidence territory.
Long-Term Effects on Children
Parents understandably want to know whether tocolytic exposure in the womb leaves any lasting marks on their child’s development. The most reassuring data come from a study of children born very preterm who were followed up to five and a half years of age. Neurodevelopmental disabilities, whether mild, moderate, or severe, did not differ between children who had been exposed to tocolytics in utero and those who had not. The study also compared children exposed to atosiban versus calcium channel blockers and found no difference in outcomes between those two drug classes.20PubMed Central. Tocolysis and Neurodevelopment of Children Born Very Preterm
The picture is less clear-cut for beta-agonists specifically. A large cohort study found that in-utero exposure to ritodrine was associated with a modestly higher risk of autism diagnosis by age eight, even after adjusting for a range of confounders including gestational age and birth weight.21Scientific Reports. In utero exposure to ritodrine during pregnancy and risk of autism in their offspring until 8 years of age However, a smaller study of toddlers exposed to beta-sympathomimetic tocolytics did not find a higher risk of autistic spectrum disorders or poorer developmental scores compared with controls, though the earliest start of tocolytic treatment in the preterm group was correlated with lower competency scores and higher problem scores.22PubMed Central. Association between Beta-Sympathomimetic Tocolysis and Risk of Autistic Spectrum Disorders, Behavioural and Developmental Outcome in Toddlers It is difficult to untangle how much of any observed association is due to the drug itself versus the underlying prematurity and its complications. Studies like these are inherently observational, and the populations who receive tocolysis tend to be at higher baseline risk. Still, the pattern of concern around beta-agonists has contributed to the broader shift toward nifedipine and atosiban as preferred agents.
How Practice Varies and Why
Which tocolytic you receive depends heavily on where you are. In much of Europe, atosiban is the dominant first-line choice. The Austrian survey cited earlier found that nearly 80% of obstetric units used atosiban first, with nifedipine a distant second at 13%.23PubMed Central. Differences between Current Clinical Practice and Evidence-Based Guideline Recommendations Regarding Tocolysis – an Austria-wide Survey In many low- and middle-income countries and in the United States, where atosiban is unavailable, nifedipine is the go-to. Beta-agonists remain common in parts of Asia. These differences reflect not just the evidence but also drug availability, regulatory approval history, cost, and local clinical tradition.
Even within a single country, what triggers a clinician to start tocolysis varies. In the Austrian survey, about half the units defined the threshold as at least four contractions within 20 minutes, a quarter used cervical shortening below 25 millimeters, and a smaller fraction relied on a positive biomarker test or even subjective reports of contractions. The variety of thresholds means that some women may receive tocolysis when their contractions would have stopped on their own, while others might be undertreated. The field has attempted to use tools like fetal fibronectin testing and cervical length measurement to improve this triage, but a study that randomly assigned women to know or not know their fibronectin results found no difference in rates of hospitalization, tocolytic use, or corticosteroid administration, suggesting the test did not meaningfully change clinical behavior in that context.24PubMed Central. Predicting preterm birth: Cervical length and fetal fibronectin
Facilitating Transfer
One underappreciated use of tocolytics is keeping contractions at bay during the physical transfer of a woman from a smaller facility to a tertiary hospital. In regions with widely distributed populations, this transfer can involve ground ambulance or even air transport over significant distances. A retrospective study of women transported during preterm labor found that nifedipine was used successfully to facilitate in-utero transfer, and nearly half of the women referred were eventually discharged without delivering preterm at all.25Air Medical Journal. Is Nifedipine as a Tocolytic Effective in Facilitating In Utero Transfer? Being born at a facility with a neonatal intensive care unit meaningfully improves survival and outcomes for very preterm infants, so this logistical role of tocolysis can be just as important as the pharmacological window it creates for steroids.
Non-Drug Approaches and Common Myths
Bed rest and intravenous hydration are two interventions that have long been offered to women in preterm labor, often alongside or before tocolytic drugs. The hydration theory goes roughly like this: dehydration can cause contractions, so replenishing fluid should stop them. A Cochrane review found no evidence to support hydration as a treatment for preterm labor. The two small available trials showed no advantage of hydration over bed rest alone.26PubMed. Hydration for treatment of preterm labour Bed rest itself has not been shown to prevent preterm birth either, and prolonged bed rest carries its own risks including blood clots, muscle loss, and psychological harm. Neither hydration nor bed rest should be considered substitutes for tocolytic medication when tocolysis is indicated.
New Drugs in the Pipeline
The current tocolytic toolkit is, by most accounts, inadequate. All existing agents come with side effects, none has been proven to reduce perinatal mortality on its own, and none can reliably prevent preterm birth in the long term. Researchers are pursuing a range of new approaches. A landscape analysis of the drug development pipeline identified over 70 candidates in clinical development for preventing preterm birth or managing preterm labor. Among the treatment candidates rated as high-potential were nicorandil (a potassium channel opener already used for angina), isosorbide dinitrate (a nitric oxide donor), nicardipine (a calcium channel blocker related to nifedipine), and celecoxib (a selective COX-2 inhibitor that may avoid some of indomethacin’s fetal risks). Medium-potential candidates included retosiban (a newer oxytocin receptor antagonist) and relcovaptan (a vasopressin receptor antagonist).27PubMed Central. New medicines for spontaneous preterm birth prevention and preterm labour management: landscape analysis of the medicine development pipeline Other investigational avenues include progesterone (already used for prevention rather than acute treatment), prostaglandin F2-alpha antagonists, and even statins.28Current Pharmaceutical Design. Safety and Efficacy of Tocolytics for the Treatment of Spontaneous Preterm Labour
Whether any of these will prove to be a genuine step forward remains to be seen. The history of tocolysis is littered with drugs that looked promising in small trials and then failed to change outcomes in larger or placebo-controlled studies. The nifedipine placebo-controlled trial discussed earlier is a sobering recent example. For now, the real advances in preterm birth outcomes continue to come less from the tocolytic itself and more from the interventions it enables: corticosteroids, magnesium sulfate for neuroprotection, and delivery in facilities prepared for very small infants.